Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Feasibility Testing of Plant-Based Supplemented Food Products Made With Manitoba Crop Ingredients for Weight Loss

15 de setembro de 2026 atualizado por: Dylan MacKay, University of Manitoba

The purpose of this study is to advance the development of the WI/CDIC supplemented foods by evaluating the acceptance and feasibility of the supplemented food bars within the Wellness Institute's Weight Loss Clinic program (WLC) or an equivalent weight loss program in Winnipeg or the surrounding area. The main questions it aims to answer are:

  • To determine whether the incorporation of WI/CDIC supplemented foods into the WI weight loss clinic design is feasible.
  • To determine whether weight loss is supported by a plant-based supplemented food.
  • To assess efficacy of the supplemented food by measuring changes in lifestyle behaviours and risk factors for chronic disease compared to non-supplemented food weight loss program members.

Researchers will compare the WLC program plus supplemented food to the WLC program without the supplemented food to evaluate the implementation of the supplemented foods into the WLC.

Participants will follow their WLC program for the initial 16 weeks, and those in the intervention group will begin their supplemented food. Participants will consume one supplemented food bar each day and will record this in the product consumption log.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

This is a pilot evaluation of the feasibility of incorporating the WI/CDIC supplemented food into the WI's newly designed WLC. This study will employ a mixed methods quasi-experimental approach using questionnaires and data collected over the evaluation period. Following consent, participants will be asked to fill out a set of questionnaires, to capture dietary intake, and to wear an activity monitor; to measure diet, physical activity, QOL and sleep before each study meeting. Eligible participants (n=40) will be randomized to intervention (supplemented food) or no intervention. Participants will attend two in-person study visits - one at the initiation and one at the completion of the 16-week weight loss program. Body weight, height, waist circumference, blood pressure and heart rate will be recorded at these two time points as well, as collected through the weight loss clinic program. Participants will also complete an exit questionnaire at the second visit that will include a 9-point hedonic scale to evaluate product acceptability.

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Manitoba
      • Winnipeg, Manitoba, Canadá, R2V 3M3
        • Seven Oaks Hospital Chronic Disease Innovation Centre
        • Contato:
        • Subinvestigador:
          • Dr Rebecca Mollard, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male or female, aged 18 years or above
  • Live within the province of MB
  • Ability to give written informed consent in English.
  • Enrolled in the Wellness Institute Weight Loss Clinic or an equivalent, approved weight loss program in Winnipeg or the surrounding area.

Exclusion Criteria:

  • Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
  • Participants with known allergies to the supplemented food ingredients
  • Has an active eating disorder

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: The WLC program plus supplemented food

Participants in weight loss clinic program will consume one supplemented food bar each day and will record this in the product consumption log.

These supplemented foods provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.

Sem intervenção: The WLC program only

Participants in the weight loss clinic only.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Feasibility of incorporating the WI/CDIC supplemented foods into the WI weight loss clinic.
Prazo: End of Study (Week 16)

Feasibility will be demonstrated if the following five criteria are met:

  1. Eligibility to randomization ratio is greater than 0.5, calculated as the ratio of individuals within the WI WLC program who were randomized to the trial to the number eligible to participate who were approached to participate.
  2. The percentage of participants who complete the 16-week program in the supplemented food arm is equivalent (plus or minus 10%) or greater than the standard arm.
  3. Follow up of greater than 85% of participant outcomes.
  4. Adherence to the supplemented food intervention calculated by consumption of >75% dispensed products as documented in the Product Consumption Log
  5. Product Acceptability using an Exit Questionnaire consisting of a 9-point hedonic box scale to assess mean acceptability values of 6 or greater (like at least slightly) in 75% or more of the participants.
End of Study (Week 16)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Changes in Body Weight
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Body weight will be measured in kg to the nearest 0.1 kg by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Waist Circumference
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Waist circumference in cm will be measured to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape measured by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in BMI
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Body Mass Index will be calculated using the formula BMI = kg/m2; where kg is the weight in kilograms and m2 is height in metres squared.

At Enrollment (Week 0) and End of Study (Week 16)
Cardiovascular Assessment
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Using the Framingham Risk Score, cardiovascular risk will be calculated based on age, HDL-C, total cholesterol, systolic blood pressure, smoking status, and diabetes status to determine the participant's 10-year risk of cardiovascular disease and identification of metabolic syndrome.

At Enrollment (Week 0) and End of Study (Week 16)
Changes is Quality of Life
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Quality of life will be measured through the SF-36 quality of life questionnaire. The SF-36 measures nine areas: physical functioning, role functioning (emotional), role functioning (physical), energy/fatigue, emotional well-being, social functioning, pain, general health, and health change. A higher score indicates greater levels of quality of life.

At Enrollment (Week 0) and End of Study (Week 16)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Changes in Systolic Blood Pressure
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Systolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Diastolic Blood Pressure
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diastolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Heart Rate
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Heart rate in beats per minute is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Physical Activity
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Measured using the International Physical Activity Questionnaire - Short Form - (IPAQ-S)

At Enrollment (Week 0) and End of Study (Week 16)
Change in Physical Activity Behaviour Patterns
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Assessed using total active minutes per day as measured by multi-directional accelerometry for 7 days. Participants will be asked to wear the accelerometer at all times.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Dietary intake behaviours will be measured through The Mindful Eating Questionnaire. The Mindful Eating Questionnaire recognizing patterns of overeating or eating in response to stress, boredom, or other emotions. Scoring is based on five categories, which include Awareness (being aware of how food looks, tastes and smells); Distraction (focusing on other things while eating); Disinhibition (eating even when full); Emotional Response (eating in response to sadness or stress); and External Cues (eating in response to environmental cues, such as advertising)

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Changes in dietary intake behaviours will be measured through the Three Factor Eating Questionnaire which is comprised of 18 items, measuring uncontrolled eating, restrained eating and emotional eating. The higher the score represents more dependency to cognition, stress or emotion the eating patterns.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Meals
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Number of meals will be captured with a meal being defined as food intake greater than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Snacks
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Number of snacks will be captured with a meal being defined as food intake less than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Energy
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Energy will be measured in kCals and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Protein
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Protein will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fat
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Fat will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Available Carbohydrates
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Available carbohydrates will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fibre
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Fibre will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Sleep Patterns
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

An ActiGraph activity monitor will be used to measure sleep quality patterns for 7 days, with participants asked to wear the monitor at all times, including when they sleep.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in High density lipoprotein cholesterol
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Low density lipoprotein cholesterol
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Triglycerides
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol and High-Density Lipoprotein Cholesterol Ratio
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Hemoglobin A1C
Prazo: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Dr Dylan MacKay, PhD, University of Manitoba

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

23 de setembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de setembro de 2024

Primeira postagem (Real)

26 de setembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data (IPD) may be placed in a repository if required by a journal for publication purposes. De-identified IPD may also be requested from the principle investigator.

Prazo de Compartilhamento de IPD

Data will become available following the publication of the primary results manuscript.

Critérios de acesso de compartilhamento IPD

Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the trial PI.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever